Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2007;14(1):14-18 Higher Rates of SSRI Prescriptions Associated with Lower Suicide Rates in Youths Suicide is the third leading cause of death in youths 10–14 years of age in the United States. Evidence shows that most youth suicide victims have mood disorders that are not being treated at the time…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(12):19-22

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(11):15-18 FDA Issues Approvable Letter for NRP104 for the Treatment of Pediatric ADHD Shire has announced that its partner New River Pharmaceuticals Inc. has received an approvable letter from the United States Food and Drug Administration for lisdexamfetamine dimesylate for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD). Final approval…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(10):15-18

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(9):14, 16-18

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(8):15-18 Patients with Treatment-Resistant Depression Maintain Improvement after Vagus Nerve Stimulation Previous studies have shown that vagus nerve stimulation (VNS) is an effective long-term therapy for patients with chronic or recurrent depression who have not responded to ≥4 antidepressant treatments. A team of researchers recently investigated the durability of…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(7):15-18, 20

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(6):14-18

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(5):15-18

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2006;13(4):15-18

Articles Print Friendly    FDA Approves Risperidone Long-Acting Injection for the Treatment of Schizophrenia The Food and Drug Administration approved risperidone long-acting injection (Risperdal Consta, Janssen) for the treatment of schizophrenia in late October. The first long-acting atypical to receive FDA approval, risperidone injection releases consistent amounts of medication over a 2-week period. Risperidone long-acting…
Read >

Articles Print Friendly   Primary Psychiatry. 2003;10(11):19,24-28 FDA Approves Memantine for the Treatment of Alzheimer’s Disease The United States Food and Drug Administration approved memantine (Namenda, Forest) for the treatment of moderate to severe Alzheimer’s disease in October. The recommended starting dosage of memantine is 5 mg QD, with a target dosage of 20 mg/day. Dosages…
Read >

Articles Print Friendly  Primary Psychiatry. 2003;10(10):24-26   FDA Approves Bupropion Extended-Release for Major Depressive Disorder The United States Food and Drug Administration approved bupropion hydrochloride extended-release (Wellbutrin XL, GlaxoSmithKline) for the treatment of adult major depressive disorder (MDD) in September. Bupropion XL should be initiated at a dosage of 150 mg/day in the morning, with…
Read >